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Abstract
Background: Generalized anxiety disorder (GAD) is one of the most reported diagnoses in psychiatry, but there is
some discrepancy between the cases identified in community studies and those identified in tertiary care. This
study set out to evaluate whether the use of clinicians as interviewers may provide estimates in a community
survey close to those observed in primary or specialized care.
Methods: This is a community survey on a randomly selected sample of 2338 adult subjects. The Advanced
Neuropsychiatric Tools and Assessment Schedule (ANTAS) was administered by clinicians, providing lifetime
diagnosis based on the DSM-IV-TR. Health-related quality of life (HR-QoL) was measured with the Short-Form Health
Survey (SF-12).
Results: Overall, 55 (2.3%) subjects met the criteria for GAD, with greater prevalence in women (3.6%) than in men
(0.9%): OR = 4.02; 95%CI: 1.96–8.26. Up to 40% of those with GAD had at least another diagnosis of mood, anxiety,
or eating disorders. The mean score of SF-12 in people with GAD was 32.33 ± 6.8, with a higher attributable burden
than in other conditions except for major depressive disorder.
Conclusions: We found a relatively lower lifetime prevalence of GAD than in community surveys based on lay
interviewers and a structured interview. The identified cases of GAD showed a strong impact on the quality of life
regardless of co-morbidity and high risk in women, suggesting a profile similar to the one identified from studies in
primary and specialized care.
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Background
Generalized anxiety disorder (GAD) is one of the most
reported mental disorders in primary care and emer-
gency services [1]. Prevalence estimates varied widely
across countries, with higher lifetime prevalence in high-
income countries than in middle−/low-income countries
(5% versus 1.5 to 3%) [2]. The fifth edition of the Diag-
nostic and Statistical Manual of Mental Disorders
(DSM-5), describes the GAD as characterized by persist-
ent, excessive, and unrealistic worry about everyday
things, usually involving more than an area, such as fi-
nance, family, health, and the future [3]. Anxiety in
GAD is difficult to control and is accompanied by many
non-specific psychological and physical symptoms, like,
among others, muscle tension, fatigue, sleep distur-
bances, difficulty in concentrating, and irritability (DSM-
5 code: 300.02) [3]. This profile of symptoms corre-
sponds to the profile described in the fourth edition of
the DSM (DSM-IV) [4] and its text revision (DSM-IV-
TR) [5], thus favoring the comparison of studies across
time.
GAD manifests high comorbidity with mood and other
anxiety disorders, up to 50% and over, depending on the
disorder and sample [2, 6]. GAD is often comorbid with
bipolar disorder (BD), and might be associated with a
more severe BD course and increased risk of suicide [7].
Role impairment is common in people with GAD and
may be severe [2], as well as the association with chronic
non-psychiatric diseases [6].
The etiology of GAD is unknown. A combination of
genetics, environmental factors such as adverse child-
hood experiences, somatic disorders (including diabetes),
alcohol and substance use, and the impact of stressful
life events is thought to contribute to the onset, the
course, and the persistence of GAD across lifetime.
Some, low quality, brain imaging studies support a role
in the expression of GAD symptoms of areas related to
decision making, memory, cognitive flexibility, emotion
appraisal and regulation, and detection of threat [8, 9].
GAD imports a high cost-of-illness, in terms of health
expenditure and lost productivity, which has been esti-
mated to be increased by a factor of 2.60 (95%CI: 2.01–
3.36) [10]. Only about half of those with GAD seek
treatment [2]. Patients with GAD may benefit from
pharmacotherapy [11, 12]. In clinical practice, a combin-
ation of benzodiazepines and antidepressants is often
prescribed [11, 12]. However, current guidelines
emphasize that benzodiazepines should be avoided for
long-term management of GAD and should be restricted
to short-term use for the risk of tolerance and depend-
ence [13, 14]. Pregabalin and quetiapine can be pre-
scribed for long-term treatment of GAD [15]. Besides
pharmacotherapy, cognitive behavioral therapy has been
proved to be effective for GAD [16], while physical
activity [17] and the application of transcranial magnetic
stimulation [18] or transcranial direct current stimula-
tion [19] may help for decreasing symptoms in GAD.
Despite GAD being one of the most reported diagno-
ses in psychiatry, and the validity of the phenotype re-
ceived some support [20], the autonomy of the diagnosis
was questioned by the findings of some epidemiological
surveys [21]. For example, some of the symptoms re-
quired for major depressive disorder (e.g.., sleep difficul-
ties, fatigue, and decreased concentration) overlap with
GAD ones (being easily fatigued, difficulty concentrating,
sleep disturbance). Indeed, the symptoms of GAD over-
lap in a large proportion with those of many other psy-
chiatric conditions and a very small percentage of people
diagnosed with GAD do not show another mental health
diagnosis (about 17%) [21]. This is against the expect-
ation of zones of rarity between syndromes [22]. Au-
tonomous entities should show identifiable
discontinuities with related conditions, with mixed con-
ditions expected to be rarer than the pure forms [23].
Eventually, the actual diagnostic algorithm of the GAD
goes into a detailed list of exclusion criteria, from obvi-
ous ones (the exclusion of the physiological effects of a
prescribed or abuse substance or of a medical condition)
to a cumbersome list of other mental disorders that
should be assessed and whose impact on the anxiety,
worry, or physical symptoms should be excluded (e.g.,
among others, anxiety or worry about having panic at-
tacks in panic disorder, negative evaluation in social anx-
iety disorder, reminders of traumatic events in
posttraumatic stress disorder, physical complaints in
somatic symptom disorder, having a serious illness in ill-
ness anxiety disorder). Such a kind of detailed evaluation
can be done in epidemiological survey but it is less easily
conducted in the clinical setting. Moreover, studies on
clinical samples provide data somewhat inconsistent
with epidemiological studies, e.g. in a special anxiety unit
in Göttingen, Germany, the proportion of patients seek-
ing help had about 50% a diagnosis of panic disorder
(frequency in epidemiological surveys around 2–3%) and
only 7.5% a diagnosis of GAD (around 4% in epidemio-
logical surveys) [24, 25].
These inconsistencies might depend on the fact that
the cases identified in community studies are not the
same as those identified in tertiary care. Indeed, in a
diagnosis in which a central symptom such as worries
has a fundamental clinical relevance, the use of “lay” in-
terviewers and structured interviews can flatten the clin-
ical relevance of the symptom’s centrality in
epidemiological surveys [26]. Conversely, in the clinical
setting greater attention is paid to patients’ reporting of
theirs worries. A competing explanation could be that
clinicians that work in specialized and tertiary care cen-
ters may overlook milder, but still burdensome
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symptoms: they may actually underdiagnose more soft
cases because their clinical judgment is biased towards
more severe and complex mental problems. Several
studies conducted in the primary medicine setting de-
scribed cases of GAD, rare in general but more frequent
in the elderly (unlike some epidemiological studies that
found greater frequency among young people), and with
a severe impairment of health-related quality of life (HR-
QoL) regardless of comorbidity with other anxiety and
depressive disorders [27, 28].
The purpose of this work is to estimate the prevalence
of GAD in a nationwide Italian sample. The impact of
GAD and its comorbidity in terms of HR-QoL will be
quantified, too. In this study, clinicians such as inter-
viewers and semi-structured interviews (instead of lay
interviewers and structured interviews like most epi-
demiological studies) will be used, and this might lead to
the identification of a GAD profile different from that of
other epidemiological studies previously conducted [29–
36].
Methods
This is an observational cross-sectional study (commu-
nity survey).
Design and procedure
The study sample was selected by randomization after
stratification in 8 cells (gender and age 18–24; 25–44;
45–64; > 64) from records of municipalities of six Italian
regions (one urban, one suburban, and at least one rural
municipalities each region). The selected regions were
representative of geographic and socio-economic charac-
teristics of the whole 20 Italian regions.
Trained physicians or clinical psychologists conducted
the interview face to face at homes of the enrolled
people. This study is a secondary research of a project
whose main objective was to study the appropriateness
of psychiatric diagnosis and use of prescribed drugs in
the Italian population. Details on the sampling proced-
ure and the characteristics of the sample can be found in
the parent article [37].
Study tools
The psychiatric interviews were conducted by means of
a semi-structured tool, the Advanced Tools and Neuro-
psychiatric Assessment Schedule (ANTAS) [37]. The
ANTAS is a computerized tool inspired to the Struc-
tured Clinical Interview for DSM-IV (SCID) [38]. The
ANTAS produces mood, anxiety and eating disorders
diagnosis according to the DSM-IV-TR [5] with high
cross-validity and reliability with SCID [37]. All diagno-
ses of psychiatric disorders were estimated as lifetime
prevalence according to DSM-IV-TR criteria.
The Mood Disorder Questionnaire (MDQ) [39, 40]
was adopted to assess lifetime subthreshold hypomanic
episodes. Despite low accuracy in screening DSM-
defined cases of bipolar disorder [41], the tool is good at
identifying subthreshold cases [42].
The 12 items Survey Short Form (SF–12) [43] was
used to measure the HR-QoL. The HR-QoL is a con-
struct encompassing the self-perception of physical and
psychological health. It is currently utilized as whole
outcome and of impairment indicator in chronic dis-
eases [44].
Statistical analysis
The odds ratio (OR) in univariate analysis for DSM-IV
TR GAD diagnosis and age, gender and comorbidity
with DSM-IV-TR diagnosed disorders, was calculated
using a single group as pivot by each table. The statis-
tical significance of the associations was measured with
the χ2, with or without Yates correction. The SF-12
mean scores between groups were compared with Ana-
lysis of Variance (ANOVA) one-way statistic.
The attributable burden on impairing HR-QoL of
GAD was measured as difference between mean score
on the SF-12 in a sample drawn from the same commu-
nity survey database of people without GAD and the
mean score of SF-12 of people with GAD. For this meas-
ure, the “healthy” control sample was obtained matching
and randomization by blocks. For each person with
GAD, a cell was created including all the people without
GAD in the database of the same age and gender, thus
four people for each cell were selected. The burden in
impairing of HR-QoL attributable to GAD was also
compared to a similar measure obtained to other dis-
eases in previous case-control studies, which were car-
ried out with the same methodology [45–51].
Ethics
The study was approved by the by the ethical committee
of the Italian National Health Institute (Rome) and con-
ducted according to the Declaration of Helsinki and its
revisions [52]. All participants signed a written informed
consent. They all received an appropriate referral to pri-
mary (general practitioner) or tertiary care (local psychi-
atric services) in case they manifest symptoms related to
the disorders under investigation.
Results
Table 1 shows lifetime prevalence of GAD by sex and
age, the overall lifetime prevalence in the sample was
2.3%, with a markedly higher frequency in women (3.6%)
than in men (0.9%; OR = 4.02; 95%CI: 1.96–8.26) and a
substantially stable frequency in age in both sexes.
The lifetime prevalence found by our research (2.3%)
is lower than the one found in all other studies that were
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conducted through structured interviews administered
by lay interviewers (Table 2).
With just the exception of the study of Chang in
Singapore (1.6%), and the European Study of the Epi-
demiology of Mental Disorders (ESEMeD) [32], with es-
timates of 2.8%, the other studies ranged from 3.6% in
Korea [34] to 10.5% in a small town in Taiwan [29].
As far as comorbidity was concerned, people with at
least another diagnosis of mood, anxiety or eating disor-
ders were 22 out 55 (40%). The most frequent diagnoses
in comorbidity were: major depressive disorders (20%,
OR = 5.97; 2.99–11.95), panic disorder (16.4%; OR =
17.4; 7.56–38.40), and simple phobia (16.3%; OR = 9.93;
4.58–21.55) (Table 3).
The level of HR-QoL in people with GAD (measured
as mean score of SF-12) was 32.33 ± 6.8, without differ-
ences in people with (N = 22; 30.4 ± 7.0) or without co-
morbidities (N = 33; 33.6 ± 6.7): F (1;53) = 2.90; p = 0.094.
Overall, with the only exception of major depressive dis-
order, GAD showed an attributable burden higher to
that observed for the other investigated disorders from
the same database (Table 4).
However, if we consider the cases of GAD without co-
morbidity, the “attributable burden” in impairing HR-
QoL becomes comparable between GAD to that of most
of the other disorders considered, except for panic dis-
order and simple phobia that resulted less impairing.
Discussion
This survey, conducted by clinical interviewers who
employed a semi-structured interview, showed a lower
frequency of GAD in a sample of Italian general popula-
tion compared to all community surveys conducted re-
cently with the use of lay interviewing and clinical
interviews structured [29–35], with the only exception of
the study of Chang in Singapore [36] and the ESEMeD
study [32]. The Chang ‘study also showed an increase
from 0.9 to 1.6% compared to a study conducted in
Singapore a few years earlier [36].
It is worth noting that our study highlights lower rates
than research conducted on samples that are culturally
closer, such as those examined by Faravelli’s study in a
center of Tuscany in Italy [33]. Compared to this study,
people with GAD in our sample have a lower frequency
of comorbidity with other mood, anxiety or eating disor-
ders (40% vs 70% of the study by Faravelli et al. [33]),
and are more frequently women (4/1 ratio instead of 2/
1). Another peculiar characteristic of our sample is that
the frequency is stable over time and there is no higher
frequency in the youth population as otherwise
highlighted in the other community surveys conducted
with structured interviews [25].
The stability of rates in different age groups, resulting
in a higher rate in the elderly population (comparing
with other community surveys) and the increased fre-
quency in women makes our sample closer to the profile
of GAD described in the specialist medical setting and/
or primary care [27, 28]. It must be noted that a disorder
like GAD, which should have a long course, should ac-
cumulate its frequency over time and, therefore, it would
be logical to expect the lifetime rates in the elderly to be
high. But this certainly applies to a disabling and high-
impact disorder, less to a mild disorder that tends to be
forgotten more frequently, generating higher recalling
bias rates [53]. Nevertheless, several investigations noted
a high prevalence of GAD in elderly people, with
Table 1 Lifetime Prevalence of GAD by sex and age
N (%) χ2 p OR 95%CI
Men
< 25 0 (0) –
25–44 3 (0.8) 0.331a 0.565 OR = Inf NV
45–64 2 (0.6) 0.854a 0.356 OR = Inf NV
> 64 4 (2.1) 0.288a 0.090 OR = Inf NV
Overall men 9 (0.9)
Women
< 25 5 (3.6)
25–44 17 (3.8) 0.007a 0.933 1.04 0.39–2.91
45–64 15 (3.1) 0.023a 0.879 0.79 0.28–2.24
> 64 9 (3.6) 0.001a 0.999 0.99 0.32–2.01
Overall women 46 (3.6)
Women vs. Men 16.770 < 0.0001 4.02 1.96–8.26
Men and women 55 (2.3%)
awith Yates’s correction






Italy (Present study) 2.3 ANTAS-SCID DSM-IV
ECA, Los Angeles [30] 4.1 DIS-DSM III
ECA, Durham, San Louis
[30]
6.6 DIS-DSM III
NCS [31] 5.1 CIDI-DSM-IIIR
NCS-R [35] 5.7 CIDI-DSM-IV
Sesto Fiorentino (Italy) [33] 5.4 / 3.9 UM-CIDI DSM-IIIR/DSM-IV
Taiwan Urban [29] 3.7 DIS-DSM III
Taiwan Small Town [29] 10.5 DIS-DSM III
Taiwan Rural [29] 7.8 DIS-DSM III
Korea [34] 3.6 DIS-DSM III
ESEMED [32] 2.8 CIDI DSM-IV
Singapore [36] 1.6 CIDI DSM-IV
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estimates around 10% or above [54–56]. A fraction of
these cases were late-onset cases of GAD triggered by
recent adverse life events and by chronic physical or
mental (depression) health disorders. Adversities during
childhood and a history of mental problems in parents
were also related to recent onset GAD [55].
The GAD profile highlighted in our sample confirms
that it has a severe impact on the lives of individuals,
even independently of co-morbidity with other disorders,
which, consistent with the cases highlighted in the pri-
mary medicine setting, defines a very well-defined path-
ology. Our study, therefore, seems to confirm that there
may be a more clinically relevant (and less extensive) nu-
cleus of people suffering from GAD and that the re-
search conducted with hyper-structured methodology
and using lay interviewers may produce an improper en-
largement of the number of disorders that it may include
people who are not properly suffering from a clinically
important condition. This can be confirmed not only by
the mismatch between the profile in community surveys
and in health care agencies (which can be determined by
barriers to access care for milder cases, although this is
unlikely about primary care) but above all from the para-
dox of a progressive decrease over time of the lifetime
frequency by age group.
The use of trained clinician interviewers is the strength
of this study, together with the application of a standard-
ized tool in community-based samples that were repre-
sentative of the socio-cultural characteristics of the
entire national territory. Nevertheless, some limitations
must be acknowledged. The target of the original study
was the lifetime prevalence of people diagnosed within
the bipolar spectrum, which was estimated to involve 4%
of participants. However, GAD and other anxiety
Table 3 Comorbidity between GAD and other disorders
Comorbid with GAD χ2 p OR 95% CI
Major Depressive Disorder 11 (20%) 32.69a < 0.0001 5.97 2.99–11.95
Obsessive-Compulsive Disorder 4 (7.3%) 6.14a 0.013 4.14 1.52–12.80
Panic Disorder 9 (16.4%) 84.75 < 0.0001 17.04 7.56–38.40
Social Phobia 1 (1.8%) 0.53a 0.467 6.01 0.72–79.94
Simple Phobia 9 (16.3%) 50.41 < 0.0001 9.93 4.58–21.55
Post-Traumatic Stress Disorder 2 (3.6%) 3.26 0.071 3.55 0.82–15.40
Eating Disorders 2 (3.6%) 0.25 0.612 1.45 0.34–6.80
Binge Eating 2 (3.6%) 3.95a 0.046 6.11 1.35–27.56
Bipolar Spectrum (MDQ+) 3 (5.4%) 0.92 0.336 1.78 0.54–5.84
aWith Yates’s Correction
MDQ Mood Disorder Questionnaire
Table 4 Attributable Burden in worsening Quality of Life due to GAD and comparison with other disorders. Attributable Burden =
Quality of Life in a matching control group without GAD (matching controls 1/4 from the community) – Quality of Life of People
with GAD






Major Depressive Disorder [45] 33.8 ± 9.2 5.6 ± 3.6 (N = 37) F (1;90) = 2.42
P = 0.123
F (1;68) = 1.13
P = 0.291
Eating Disorders [46] 34 ± 6.2 4.4 ± 6.6 (N = 60) F (1;113) = 4.77
P = 0.032
F (1;91) = 0.17
P = 0.681
Panic Disorder [47] 35.5 ± 4.6 2.9 ± 0.9 (N = 123) F (1;176) = 166.01
P < 0.0001
F (1;154) = 43.56
P < 0.0001
Simple Phobia [48] 35.8 ± 6.1 2.5 ± 2.4 (N = 54) F (1;107) = 64.98
P < 0.0001
F (1;84) = 18.12
P < 0.0001
Post-Traumatic Stress Disorder [49] 36.3 ± 6.1 3.9 ± 1.0 (N = 26) F (1;79) = 21.03
P < 0.0001
F (1;57) = 2.82
P = 0.099
Obsessive-Compulsive Disorder [50] 35.4 ± 6.9 2.9 ± 6.0 (N = 88) F (1;141) = 17.39
P < 0.0001
F (1;119) = 3.36
P = 0.069
Agoraphobia [51] 35.2 ± 7.8 3.4 ± 3.6 (N = 35) F (1;88) = 20.93
P < 0.0001
F (1;66) = 3.55
P = 0.064
GAD 32.3 ± 6.8 6.5 ± 2.8 (N = 55)
GAD without comorbidity 33.6 ± 6.7 4.9 ± 2.9 (N = 33)
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disorders have lower lifetime prevalence, thus we were
somehow underpowered to estimates some comorbid as-
sociations. We also lack information on somatic comor-
bidities, which may be relevant in GAD and reinforce
the symptoms of anxiety in the disorder [6, 57].
Conclusions
Our community survey conducted with a methodology
that used clinical interviewers and a semi-structured
interview showed a relatively low GAD frequency in the
community than in other community surveys based on
lay interviewers and a structured interview. The charac-
teristics of the GADs of our sample (as a strong impact
on the quality of life regardless of co-morbidity and high
risk in women) indicate a disorder with characteristics
very similar to those identified from studies in primary
care and specialized care agencies.
It should be noted that there is no undisputable gold
standard about GAD and, given the essential differences
between the focus and scope of the clinician-based and
lay-administered assessment methods, it cannot be de-
cided whether the prevalence estimates of this study are
more precise than those that can be derived from epi-
demiological studies based on lay-administered assess-
ment methods. Only a direct comparison of the methods
may consent an answer to that.
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